3rd Millennium Inc., of Cambridge, Mass., promoted Eric Meyers to chief operating officer.
Aastrom Biosciences Inc., of Ann Arbor, Mich., appointed Michael Durski vice president, finance and administration, and chief financial officer.
Alexion Pharmaceuticals Inc., of Cheshire, Conn., elected David Keiser president and chief operating officer.
Aspira Biosystems Inc., of South San Francisco, named Michael Nemzek executive vice president of business development.
Aviva Biosciences Corp., of San Diego, appointed Eric Lachenmeier director of business development.
AxCell Biosciences, of Newtown, Pa., a subsidiary of Cytogen Corp., appointed Tony Hunter and Marius Sudol to its scientific advisory board.
Biogen Inc., of Cambridge, Mass., elected Eckhard Pfeiffer to its board.
Biomira Inc., of Edmonton, Alberta, appointed Nancy Wysenski to its board and Guy Ely vice president, clinical and regulatory affairs.
Cephalon Inc., of West Chester, Pa., appointed John Farah vice president, worldwide business development, and Robert Knecht vice president, information technology and services.
Enzon Inc., of Piscataway, N.J., appointed Ulrich Grau chief scientific officer.
EpiTan Ltd., of Melbourne, Australia, added Alan Cooper to its board.
Prima Biomed Ltd., of Melbourne, Australia, appointed Malcolm Brandon chairman of its scientific advisory board.
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., added Suzanne Blaug as vice president of marketing and sales, Eric Furfine as vice president of preclinical development and Barbara Tardiff as vice president of clinical informatics.
Solexa Ltd., of Cambridge, UK, added Sam Eletr to its board and appointed Tony Smith as chief technology officer.
Sprout Group, of New York, promoted Ron Hunt to partner for healthcare technology investments.
Syrrx Inc., of San Diego, appointed Steve Kaldor chief scientific officer.
TherImmune Research Corp., of Gaithersburg, Md., added Jim Turpin as associate director of infectious disease and immunology.
Vertex Pharmaceuticals Inc., of Cambridge, Mass., named Michael Wokasch president of Aurora Biosciences.